Clinical trial · Interventional
Using Mesenchymal Stem Cells to Fill Bone Void Defects in Patients With Benign Bone Lesions
NCT00851162CI-TRIAL-00008550withdrawnPhase 2 / Phase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study was not continued due to lack of enrollment.
Summary
Brief summary (as posted)
The purpose of this study is to determine whether using mesenchymal stem cells will heal benign bone lesion defects faster than demineralized bone matrix
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bone Neoplasms | Bone Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Demineralized bone matrix(DBM) | Biological | — | UNRESOLVED |
| Trinity multipotent stem cells | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Trinity
- description
- Trinity multipotent stem cells
- interventionNames
- Biological: Trinity multipotent stem cells
- type
- ACTIVE_COMPARATOR
- label
- Demineralized bone matrix
- description
- Demineralized bone matrix
- interventionNames
- Biological: Demineralized bone matrix(DBM)
Primary outcomes (1)
- measure
- Time to fill bony defect
- timeFrame
- Two to 52 weeks
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 11 Years
Show eligibility criteria text
Inclusion Criteria: * Ages \> 11 years * Benign bone lesion Exclusion Criteria: * Previous surgery
References
Publications (0)
Data not yet available
No reference posted for this study.